Latest News
Rinicare and The University Hospitals of Morecambe Bay NHS Trust are delighted to announce that they have received funding support from Innovate UK to proceed with a joint research project that will collect real-life evidence of the benefits of Ri...
Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund.
Biohabit are developing a salivary test for diagnosis of heart failure, that hopes to replace the need for...
Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis.
The IND is a crucial milestone in t...
Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial...
Dose-escalation starting at a dose based on results from a European study sponsored by partner, Menarini Ricerche.
Phase I program includes two U.S. expansion cohorts: (1) High risk cohort of HER2 negative, Hormone receptor positive (HER2-/HR+) c...